Rational combination therapy in refractory migraine

Headache

Volumn 48, Issue 6, 2008, Pages 805-819

  Peterlin, B Lee ^a   Calhoun, Anne H ^b   Siegel, Sherry ^c   Mathew, Ninan T ^d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c King Pharmaceuticals Inc   (United States)

^d Houston Headache Clinic   (United States)

Author keywords

Chronic migraine; Headache; Migraine; Migraine prevention; Rational combination therapy; Refractory migraine

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DULOXETINE; ESTRADIOL; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; NADOLOL; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PROPRANOLOL; PROTRIPTYLINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TIMOLOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VERAPAMIL; VITAMIN;

AGITATION; AGRANULOCYTOSIS; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY; ASTHENIA; ATAXIA; ATRIOVENTRICULAR BLOCK; BLEEDING; BLISTER; BLOATING; BLURRED VISION; BODY TEMPERATURE DISORDER; BRAIN DISEASE; BREAST TENDERNESS; BRONCHOSPASM; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COGNITIVE THERAPY; COLD EXTREMITY; COMORBIDITY; CONFUSION; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; EDEMA; EJACULATION; EXERCISE TOLERANCE; FAMILY HISTORY; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEPATITIS; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INSOMNIA; IRRITABILITY; LUNG EMBOLISM; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; MYALGIA; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEURAL TUBE DEFECT; ONSET AGE; ORGASM; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PARESTHESIA; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RASH; REFRACTORY MIGRAINE; REVIEW; RISK FACTOR; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN EXFOLIATION; STROKE; SWEATING; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; UNSTEADINESS; URINARY FREQUENCY; VEIN THROMBOSIS; VIVID DREAM; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

BOTULINUM TOXINS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; NERVE BLOCK; PAIN, INTRACTABLE; TREATMENT OUTCOME;

EID: 44849115002     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.01142.x     Document Type: Review

References (90)

1. Lipton RB, Bigal ME, Diamond M, et al. Advisory group migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 68 : 343 349.
2. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998 38 : 497 506.
3. Katsarava Z, Schneeweiss Kurth T, Kroener U, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004 62 : 788 790.
4. Freitag FG, Kozma CM, Slaton R, Osterhaus JT, Barron R. Characterization and prediction of emergency department use in chronic daily headache patients. Headache. 2005 45 : 891 898.
5. Ferrari A, Leone S, Vergoni AV, et al. Similarities and differences between chronic migraine and episodic migraine. Headache. 2007 47 : 65 72.
6. Stewart WF, Lipton RB, Simon D. Work-related disability: Results from the American migraine study. Cephalalgia. 1996 16 : 231 238.
7. Foley KA, Cady R, Martin V, et al. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005 45 : 538 545.
8. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines. Neurology. 2002 58 : 169 178.
9. Walker MC, White HS, Sander JWAS. Disease modification in partial epilepsy. Brain. 2002 125 : 1937 1950.
10. Pitkänen A, Narkilahti S, Bezvenyuk Z, Haapalinna A, Nissinen J. Atipamezole, an alpha(2)-adrenoceptor antagonist, has disease modifying effects on epileptgenesis in rats. Epilepsy Res. 2004 61 : 119 140.
11. Peterlin BL, Ward TN. Neuropsychiatric aspects of migraine. Curr Psychiatry Rep. 2005 7 : 371 375.
12. Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol. 2005 18 : 305 310.
13. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006 46 : 1334 1343.
14. Bigal ME, Sheftell FD, Rapoport AM, Tepper SJ, Lipton RB. Chronic daily headache: Identification of factors associated with induction and transformation. Headache. 2002 42 : 575 581.
15. Oates LN, Scholz MJ, Hoffert MJ. Polypharmacy in a headache centre population. Headache. 1993 33 : 436 438.
16. Grazzi L, Usai S, Bussone G. Chronic headaches: Pharmacological and non-pharmacological treatment. Neurol Sci. 2007 28 : S134 137.
17. Ramadan NM. Current trends in migraine prophylaxis. Headache. 2007 47 : S52 S57.
18. Mathew NT. The prophylactic treatment of chronic daily headache. Headache. 2006 46 : 1552 1564.
19. Calhoun AH. A novel specific therapy specific prophylaxis for menstrual-associated migraine. South Med J. 2004 97 : 819 822.
20. Martin V. Targeted treatment strategies for menstrual migraine. J Fam Pract. 2007 56 (2 Suppl S13 22.
21. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo controlled trial. Headache. 2005 45 : 293 307.
22. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache. 2005 45 : 315 324.
23. Afridi AK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes-prolonged effects from a single injection. Pain. 2006 122 : 126 129.
24. Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a ß-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003 23 : 961 962.
25. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand. 2007 115 : 81 83.
26. Tfelt-Hansen P, Rolan P. β-adrenoceptor blocking drugs in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA : Lippincott Williams Wilkins 2006 : 519 528.
27. Szelenyi J, Kiss JP, Vizi ES. Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. J Neuroimmunol. 2000 103 : 34 40.
28. Sareen L, Stein M. A review of the epidemiology and approaches to the treatment of social anxiety disorders. Drugs. 2000 59 : 497 509.
29. Pabis DJ, Stanislav SW. Pharmacotherapy of aggressive behavior. Ann Pharmacother. 1996 30 : 278 287.
30. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention [AHA Scientific Statement]. Circulation. 2007 29 : 2761 2788.
31. Toda N, Tfelt-Hnsen P. Calcium antagonists in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA : Lippincott Williams Wilkins 2006 : 539 544.
32. Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003 60 : 120 121.
33. Sangiorgi S, Mochi M, Riva R, et al. Abnormal platelet mitochondrial function in patients affected by migraine with and without aura. Cephalalgia. 1994 14 : 21 23.
34. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology. 2005 64 : 713 715.
35. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1998 50 : 466 470.
36. Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA. 1990 21 : 1711 1713.
37. Peto R, Gray R, Collins R, Wheatly K, Hennekens C, Jamrozik K. Randomized trial of prophylactic daily aspirin in male British doctors. BMJ. 1988 21 : 313 316.
38. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002 22 : 345 353.
39. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998 5 : 24 27.
40. Yonker ME. Pharmacologic treatment of migraine. Curr Pain Headache Rep. 2006 10 : 377 381.
41. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 26 : 188 198.
42. Peterlin BL, Loder EW. Premenstrual headache: Diagnostic and pathophysiologic considerations. Curr Headache Rep. 2006 5 : 193 199.
43. Evers S, Mylecharane EJ. Nonsteroidal anti-inflammatory and miscellaneous drugs in migraine prophylaxis. In : Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA : Lippincott Williams Wilkins 2006 : 553 566.
44. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Medicine 2000 79 : 201 209.
45. Cohen GL. Protriptyline, chronic tension-type headaches, and weight loss in women. Headache. 1997 37 : 433 436.
46. Young WB, Rozen TD. Preventive treatment of migraine: Effect on weight. Cephalalgia. 2005 25 : 1 11.
47. Suzuki J, Tsubone H, Sugano S. Characteristics of electrocardiographic changes with some representative antiarrhythmic drugs in adult rats. J Vet Med Sci. 1991 53 : 779 787.
48. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med. 2007 8 (Suppl. 2 S63 74.
49. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007 21 : 499 511.
50. Ifergane G, Buskila D, Simiseshvely N, Zeev K, Cohen H. Prevalence of fibromyalgia syndrome in migraine patients. Cephalalgia. 2006 26 : 451 456.
51. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 52 : 1264 1273.
52. Peterlin BL, Ward TN, Levin M. Antiepileptic drugs in migraine. Headache. 2005 16 : 18 36.
53. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR Clinical Affairs Product Support Study - 168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry. 2006 67 : 1698 1706.
54. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006 26 : 61 66.
55. Vieta E, Manuel GOikolea J, Martinez-Aran A, et al. A double-blind, randomized, placebo-controlled, prophylaxis of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006 67 : 473 477.
56. Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005 76 : 1730 1732.
57. Martin VT, Behbehani M. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis - Part I. Headache. 2006 46 : 3 23.
58. Tietjen GE, Bushnell CD, Herial NA, Utley C, White L, Hafeez F. Endometriosis is associated with prevalence of comorbid conditions in migraine. Headache. 2007 47 : 1069 1078.
59. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007 47 : 27 37.
60. Calhoun AH The mystery of figure 2" - A case for ovulatory migraine? Headache. 2007 47 : 1229 1230.
61. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am. 2000 27 : 705 721.
62. American College of Obstetricians and Gynecologists. Hormonal contraception. ACOG Technical Bulletin. Number 198-October 1994. Int J Gynaecol Obstet. 1995 48 : 115 126.
63. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004 190 : S5 22.
64. Thorneycroft I, Klein P, Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav. 2006 9 : 31 39.
65. Graziottin A. A review of transdermal hormonal contraception: Focus on the ethinylestradiol/norelgestromin contraceptive patch. Treat Endocrinol. 2006 5 : 359 365.
66. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005 46 : 1414 1417.
67. Kiley J, Hammond C. Combined oral contraceptives: A comprehensive review. Clin Obstet Gynecol. 2007 50 : 868 877.
68. Heymann WR. Oral contraceptives for the treatment of acne vulgaris. J Am Acad Dermatology. 2007 56 : 1056 1057.
69. Rapkin AJ, Winer SA. Drospirenone: A novel progestin. Expert Opin Pharmacother. 2007 8 : 989 999.
70. ACOG Practice Bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006 107 : 1453 1472.
71. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004 3 : 354 361.
72. Davies GC, Feng LX, Newton JR, Dieben TO, Coelingh-Bennink HJ. Ovarian activity and bleeding patterns during extended continuous use of a combined contraceptive vaginal ring. Contraception. 1992 46 : 269 278.
73. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs continuous oral contraceptive use. Contraception. 2006 73 : 235 243.
74. Schwartz JL, Creinin MD, Pymar HC, Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol. 2002 99 : 177 182.
75. Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 2: Mechanisms. Sleep. 2002 25 : 499 506.
76. Stefanick ML. Estrogens and progestins: Background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med. 2005 118 (Suppl. 12B 64 73.
77. Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation. 2005 112 : 3495 3500.
78. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 288 : 321 333.
79. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 280 : 605 613.
80. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000 133 : 933 941.
81. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004 291 : 1701 1712.
82. Ettinger B, Barrett-Connor E, Hog LA, Vader JP, Dubois RW. When is it appropriate to prescribe postmenopausal hormone therapy? Menopause. 2006 13 : 404 410.
83. Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: Outcome at 3 years. Headache. 2002 42 : 483 490.
84. Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on brush allodynia and pain in migraine. Headache. 2005 45 : 350 354.
85. Caputi CA, Firetto V. Therapeutic blockade of greater occipital and supraorbital nerves in migraine patients. Headache. 1997 37 : 174 179.
86. Sundaraj SR, Ponciano P, Johnstone C, Noore F, Castro M. Treatment of chronic refractory intractable headache with botulinum toxin type A: A retrospective study. Pain Pract. 2004 4 : 229 234.
87. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005 80 : 1126 1137.
88. Dodick D, Blumenfeld A, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clin Dermatol. 2004 22 : 76 81.
89. Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991 11 : 251 256.
90. Pascual J, El Berdei Y, Gómez-Sánchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. Headache. 2007 8 : 90 93.